Rezvilutamide Tablets (brand name: Airuian) have been included in the National Medical Insurance Catalog. The medical insurance payment standard is 863 US dollars per box. After medical insurance reimbursement (the reimbursement rate for employee medical insurance is generally no less than 70%, and for resident medical insurance no less than 60%), patients’ actual out-of-pocket costs are greatly reduced. For instance, patients covered by employee medical insurance pay approximately 345 US dollars per box. The specific expense is subject to the type of insurance and regional policies.
1. Core Price Information
Medical Insurance Pricing
After national medical insurance negotiation, the official medical insurance payment price of Rezvilutamide Tablets is 863 US dollars per box (specification: 80mg × 84 tablets/box).
Original Price Comparison
Before inclusion in medical insurance, the price of this drug was about 2,854 US dollars per box, representing a price reduction of approximately 70% after medical insurance coverage.
Actual Out-of-Pocket Costs
Employee medical insurance
Reimbursement rate ≥70%, out-of-pocket cost ≈ 43 US dollars/box.
Resident medical insurance
Reimbursement rate ≥60%, out-of-pocket cost ≈ 345 US dollars/box.
2. Factors Affecting Final Expenses
Medical insurance type and policies
Detailed reimbursement rules (e.g., deductible, maximum payment limit) in different regions may affect the final out-of-pocket ratio.
Purchase channels
Settlements in hospitals or medical insurance-designated pharmacies follow the medical insurance price strictly.
Prices in non-medical insurance channels may be higher, without reimbursement benefits.
Regional differences
Some pharmacies in first-tier cities may set slightly higher prices due to operating costs, while those in third- and fourth-tier cities may be lower; the difference is significantly narrowed after medical insurance reimbursement.
3. Medication Precautions
Indications
Restricted to patients with high tumor burden metastatic hormone-sensitive prostate cancer (mHSPC), to be used strictly under medical advice.
Long-term use
The drug should be taken continuously until disease progression or intolerable side effects occur; regular re-examinations are required to evaluate efficacy and safety.
Contraindicated populations
Not recommended for patients with moderate to severe hepatic or renal insufficiency. Hepatic and renal functions should be monitored during treatment.
